5 Results for "

H2A ubiquitination

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "H2A ubiquitination" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-18643
CAS No.: 1002789-86-7
Research Areas:  

Cancer

TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and apoptosis, and inhibits the proliferation and migration of metastatic human breast cancer cells .
loading...
    loading...
Cat. No.: HY-139514
CAS No.: 2396639-11-3
Purity:  99.42%
Target:  

E1/E2/E3 Enzyme

Research Areas:  

Cancer

RB-3, a polycomb repressive complex 1 (PRC1) inhibitor, binds to RING1B-BMI1f, with a Kd of 2.8 μM .
loading...
    loading...
Cat. No.: HY-160924
Research Areas:  

Cancer

MS147 is a VHL-based PROTAC degrader of BMI1 and RING1B (polycomb repressive complex 1 core components). MS147 directly binds EED and VHL E3 ligase, recruiting the ligase to the EED-BMI1/RING1B complex to induce time-dependent, ubiquitination-mediated degradation of BMI1 and RING1B. MS147 reduces histone H2A Lys119 mono-ubiquitination without altering histone H3 Lys27 tri-methylation and inhibits cancer cells proliferation. MS147 can be used for the research of cancer, such as chronic myelogenous leukemia and b-cell lymphoma .
loading...
    loading...
Cat. No.: HY-151799
CAS No.: 2765180-17-2
Purity:  98.62%
Research Areas:  

Cancer

P62-RNF168 agonist-1 (compound 5a) is a low cytotoxicity P62-RNF168 agonist that enhances the interaction between P62 and RNF168. P62-RNF168 agonist-1 induces a reduction in H2A ubiquitination mediated by RNF168 and impairs homologous recombination-mediated DNA repair. P62-RNF168 agonist-1 also inhibits the growth of xenograft tumors in mice in a dose-dependent manner .
loading...
    loading...
Cat. No.: HY-163518
Target:  

E1/E2/E3 Enzyme

Research Areas:  

Cancer

Antitumor agent-153 (compound 11b) is an optimized H2A histone ubiquitination inhibitor based on PRT4165 (HY-19817). Antitumor agent-153 inhibits the viability of human osteosarcoma U2OS cells and reduces histone H2A monoubiquitination, exhibiting anticancer activity .
loading...
    loading...